Oncimmune
Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK with operations in Germany and USA.
Dr Mike Fisher
Vice President, Head of Business Development
PrecisionLife
- Multi-target R&D Partnership: Strategic R&D partnership with Ono Pharmaceutical to discover and validate multiple novel therapeutic targets in CNS, signed in Dec'22
- Precision Neuroscience Partnership: Collaboration with Sosei Heptares for deeper evaluation of one of their GPCR targets, signed in Nov'22
Dr Georgia Gliki
Vice President Business Development
Gianluca Valenza
Business Development Director
Research Donors
Research Donors collects, processes and delivers human blood biospecimens that meet the most demanding research requirements. With a diverse community of over 2500 donors, we can meet any donor specification as required by your project. Fresh HLA typed human leukopaks, PBMCs, whole blood and blood derivatives, all consented for commercial and genetic research, can be delivered within 24 hours of collection across Europe.
Research Donors only provides samples that have been collected under the most stringent levels of ethics and consent. All our samples are:Collected from donors with full genetic & commercial research consent
Collected & processed in a UK ISO accredited facility
Samples anonymised but traceable to origin Research Donors is:
A Human Tissue Authority (HTA) licensed establishment: License Number 12693
A Health Research Authority (HRA) ethically approved research tissue bank
Dr Vashu Pamnani
Senior Business manager
Rosemont Pharmaceuticals
Rosemont Pharmaceuticals is a UK-based pharmaceutical company that has been manufacturing and commercialising a range of prescription based liquid medicines for more than 50 years, all of which are designed for use by patients that experience swallowing difficulties / dysphagia (ie paediatric and/or geriatric patients).
Partnering with Rosemont gives you access to our unique expertise in liquid medicines, a continuously growing portfolio of innovative medicines and the latest technology in both R&D and manufacturing.
At our state-of-the-art manufacturing site in Leeds, United Kingdom, we produce over 4 million bottles of liquid medicine every year. Our focus on research and development is the key to growth in our portfolio and we continuously invest in our facilities to ensure we have the latest technologies to enhance our capabilities and capacity.
We have a portfolio of over 130 oral liquid medicines across a range of therapeutic areas including 70 licensed products.
All of our products, both licensed and ‘specials’ are made to the same exacting standards under GMP. Our UK range also includes 9 products licensed for use with PEG/NG tubes. We are always seeking to expand our range of medicines and covert our ‘specials’ to licensed product wherever possible.
Laszlo Kodaj
International Sales Manager Rx
S. M. Discovery Group (SMDG)
SMDG is a biotechnology company dedicated to delivering efficacious, safe and disease modifying therapies to save lives and improve health.
Through our R&D, we are addressing the lack of safe and effective gene therapies for some of the most debilitating diseases, particularly neurological and rare diseases. We have developed a patent protected biotechnology platform for targeted delivery of nucleic acid medicines across biological barriers, such as the blood-brain barrier and have an expanding intellectual property portfolio including granted and pending patents.
* SMDG has been recognised as a Life Science Innovator 2023 (one of UK most innovative companies)
* SMDG’s NLC technology platform was recognized as one of the break-through and significant/notable (findings and technologies reported) papers of 2019 by the Fluids and Barriers of the CNS (2020 publication). * SMDG was a finalist in 2021 in the UK Bionow awards.
* SMDG’s disruptive technology has been profiled in over 160 global media outlets, journals, biotechnology and medical news.
* SMDG has received funding from the European Commission, UK Department of Trade, UK. Innovation SuperNetwork, European Union Regional Development Fund, UK North East Local Enterprise Partnership.
Dr Z. Shadi Farhangrazi
Chief Executive Officer
S. Moein Moghimi
Chair, Science Advisory Board and Co Founder
Scendea
Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Our origin dates back over 20 years, with involvement in over 1,000 development programmes.
Our international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval. Our scientific excellence, industry experience, commercial awareness and a collaborative approach allow our expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements. At Scendea we collaborate, innovate, and together with our clients, we succeed.
Claire Martin
CBO
Stuart Hunter
Senior Business Development Manager
